Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

829 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Jacobsson L, Loft AG, Iannone F, Fagerli KM, Vencovsky J, Santos MJ, Möller B, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Cefle A, Eklund K, Codreanu C, Jones G, van der Sande M, Wallman JK, Sebastiani M, Michelsen B, Závada J, Nissen MJ, Sanchez-Piedra C, Tomšič M, Love TJ, Relas H, Mogosan C, Hetland ML, Østergaard M. Ørnbjerg LM, et al. Among authors: ostergaard m. J Rheumatol. 2024 Apr 1;51(4):378-389. doi: 10.3899/jrheum.2023-0764. J Rheumatol. 2024. PMID: 38224992 Free article.
No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation.
Døhn UM, Skjødt H, Hetland ML, Vestergaard A, Møller JM, Knudsen LS, Ejbjerg BJ, Thomsen HS, Ostergaard M. Døhn UM, et al. Among authors: ostergaard m. Clin Rheumatol. 2007 Nov;26(11):1857-61. doi: 10.1007/s10067-007-0589-y. Epub 2007 Feb 27. Clin Rheumatol. 2007. PMID: 17332974
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Hjardem E, Østergaard M, Pødenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rødgaard A, Skøt J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML. Hjardem E, et al. Among authors: ostergaard m. Ann Rheum Dis. 2007 Sep;66(9):1184-9. doi: 10.1136/ard.2006.054742. Epub 2007 Mar 27. Ann Rheum Dis. 2007. PMID: 17389656 Free PMC article.
Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
Ostergaard M, Unkerskov J, Linde L, Krogh NS, Ravn T, Ringsdal VS, Petri A, Andersen LS, Tarp U, Hansen A, Hjardem E, Hetland ML. Ostergaard M, et al. Scand J Rheumatol. 2007 Mar-Apr;36(2):151-4. doi: 10.1080/03009740601089267. Scand J Rheumatol. 2007. PMID: 17476624 No abstract available.
Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
Hetland ML, Lindegaard HM, Hansen A, Pødenphant J, Unkerskov J, Ringsdal VS, Østergaard M, Tarp U. Hetland ML, et al. Among authors: ostergaard m. Ann Rheum Dis. 2008 Jul;67(7):1023-6. doi: 10.1136/ard.2007.087262. Epub 2008 Feb 13. Ann Rheum Dis. 2008. PMID: 18272669
829 results